DeBeurs.nl

aossa 24 februari 2007 18:10

0

www.aidshivresearch.com/showtrial.php...

Sponsor(s): Merck

Conditions to be treated: HIV Infection

Purpose: This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is patient driven. Investigators are not proactively assigned. There is no target sample size and duration of the study is indefinite. For information on how to enroll in the study, see link below.

Interventions:
Drug:MK0518
Current phase(s) of study:
Phase III
Study type: Expanded Access
Age limit of subjects: 16 years of age and up
Genders eligible for study: Both

Official title: Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options

Important dates:
Start Date: 2006-10-01

Contact information for recruiting centers:
Call for Information, Horsham, Pennsylvania, 19044, United States

[verwijderd] 27 februari 2007 09:53

0

quote:
flosz schreef:
[quote=flosz]
'Two of the most advanced trials underway in 2007 are from Sanofi-Pasteur and Merck & Co., Inc. Data from Merck’s ongoing Phase IIb test-of-concept trial with its adeno-5 vector vaccine candidate is expected in late 2007 or early 2008 and will provide preliminary information on the efficacy of this type of vaccine candidate. These results will have significant implications for the field's future research and development efforts. The company will also soon be starting an additional Phase IIb trial with the same candidate in South Africa.
[/quote]
Press Releases
February 8, 2007

First Large-Scale HIV Vaccine Trial in South Africa Opens
Four-year trial will enroll 3,000 participants throughout South Africa

A large-scale clinical trial of a candidate HIV vaccine—which previously showed promise in smaller studies in the United States and elsewhere—has now opened in South Africa. The study plans to enroll up to 3,000 HIV-negative men and women, making it the largest African HIV vaccine trial to date.

Conducted jointly by the South African AIDS Vaccine Initiative (SAAVI) and the HIV Vaccine Trials Network (HVTN), the trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study vaccine, provided by Merck & Co. Inc. (Whitehouse Station, NJ), contains copies of only three HIV genes, not the entire virus, so it is impossible for a trial volunteer to become infected from the vaccine.

“Our best hope of ending the AIDS epidemic is a safe and effective vaccine,” says NIH Director Elias A. Zerhouni, M.D. “To achieve that goal requires the concerted effort of governments, scientists and private industry as well as participation by well-informed volunteers.”

In South Africa the trial is called Phambili (“moving forward”). Also known as HVTN 503, it is a Phase IIb “test-of-concept” trial, the first such vaccine study in South Africa. This type of trial is designed to provide preliminary information on vaccine efficacy and thus enable researchers to decide whether or not to conduct a larger Phase III efficacy trial that could lead to licensure.

In smaller trials, the vaccine was found to be safe and to stimulate cellular immune responses against HIV in more than half of volunteers. To date, more than 1,800 people have received at least one injection. Two years ago, the first Phase IIb trial of the vaccine opened at sites in the United States, Canada, South America, Australia and the Caribbean (see www3.niaid.nih.gov/news/newsreleases/..., areas where a subtype of HIV called clade B predominates. That trial is ongoing.

www.hvtn.org/media/pr/phamni.html

Date: Feb 9, 2007
Title: KPLU interviews Larry Corey on the state of HIV vaccine research
Source: KPLU radio (audio file)
Summary: Dr. Larry Corey discusses Phambili, the first large-scale efficacy HIV vaccine trial in South Africa.
stream.publicbroadcasting.net/product...

[verwijderd] 28 februari 2007 17:50

0

14Th. Conference on Retroviruses and Opportunistic Infections

Los Angeles, February 25-28, 2007.

Symposium: T-Cell Based Vaccines: Promise of Clinical Efficacy?
Feb 27, 2007 2:00 PM

Strategies to Overcome Pre-existing Vector-specific Immunity
Dan Barouch
Beth Israel Deaconess Med Ctr, Boston, MA, US
app2.capitalreach.com/esp1204/servlet...

www.retroconference.org/2007/data/fil...

[verwijderd] 28 februari 2007 17:54

0

Source: Queensland University of Technology
Date: February 28, 2007
More on: Nature of Water, Viruses, Technology, Medical Imaging, Electronics, Inorganic Chemistry

Sifting Out Cure For HIV: Special Ceramic Membranes Could Filter Virus From Blood
Science Daily — HIV may one day be able to be filtered from human blood saving the lives of millions of people, thanks to a world-first innovation by Queensland University of Technology scientists.

QUT Associate Professor Dr Huaiyong Zhu. (Image courtesy of Queensland University of Technology)QUT scientists have developed specially designed ceramic membranes for nanofiltration, which are so advanced they have the potential to remove viruses from water, air and blood.

Associate Professor Huaiyong Zhu, from QUT's School of Physical and Chemical Sciences, is leading the development of these membranes, also known as nano-mesh, and said preliminary research had proved it successful in removing viruses from water.

Nanofiltration is the filtration of minute particles using a filter with extremely small pores.

"If we can remove compounds from liquids and viruses from water, then there may also be potential to remove HIV from blood," Dr Zhu said.

Dr Zhu said current ceramic membranes were unable to permit high filtration flux or flow, and at the same time effectively filter out unwanted particles or viruses.

He said another failing of current membranes was they often formed pin-holes and cracks during the fabrication process, resulting in wasted membranes.

"With this in mind we have introduced radical changes to the membrane texture because it is the membrane texture which is crucial to the separation efficiency of the material," he said.

"It is scientifically known that a mesh structure is the most efficient form of filtration and we are the first group to successfully construct such a structure on a nanometre scale with ceramic fibres.

"This modification has increased the rates of flow that pass through the membranes by at least ten times compared with current ceramic membranes, while maintaining the efficiency of capturing over 96 per cent of the unwanted particles."

Dr Zhu said the membranes, which have been patented by QUT, were not solely restricted to blood filtration and could also be used to filter water and air.

"For example this technology could be used to filter airborne viruses such as the Severe Acute Respiratory Syndrome (SARS) and the avian flu virus, both of which are currently a major concern to the international community."

He said because the membrane was designed to permit a large flux or flow, it could also be used for water treatment, as well as within the pharmaceutical and food industries.

Another benefit of the technology is that the alumina and titania nanofibres are made from compounds produced in abundance in Australia.

"It's literally home-grown technology," he said.

"Titania is a compound found in beach sand and alumina is an intermediate product of aluminium which is the third most abundant element in the earth's crust.

"Australia is the largest producer of alumina and titania in the world meaning we can make nano-mesh relatively easily and cheaply."

But Dr Zhu said the future of nano-mesh relied on attracting an industry partner interested in developing the technology into a commercial product.

"We have proven the technology works, so the initial research has been done," he said.

"We now need a partner to come on board and help us develop this technology into a product that has the potential to save the lives of people with HIV."

Note: This story has been adapted from a news release issued by Queensland University of Technology.

New! Search Science Daily or the entire web with Google:

[verwijderd] 28 februari 2007 19:00

0

VAX Primer: Understanding Neutralizing Antibodies

Why are HIV-specific neutralizing antibodies so difficult to induce with vaccination?
The human immune system uses many different types of defenses to combat pathogens such as viruses and bacteria, and these can be divided into two broad categories known as innate and adaptive immunity (see VAX February and March 2004 Primers on Understanding the Immune System, Parts I and II). The innate immune responses are the first responders on the scene when the body encounters a new pathogen. They can either prevent an infection or limit it until additional help from the immune system can be rallied. Often this additional help is necessary and this is where adaptive immunity kicks in. Adaptive immune responses are customized to act upon a particular pathogen, such as HIV. These adaptive immune responses are further divided into two main branches—cellular and humoral immunity. Cellular immune responses are carried out by cells known as CD4+ T helper cells that orchestrate the activities of another group of cells known as cytotoxic T lymphocytes (CTLs) that can kill cells infected with a particular virus. Humoral immunity consists of cells called B cells that generate antibodies, which are Y-shaped protein molecules that can latch onto specific viruses and thereby block them from infecting cells.
Why are antibodies important?
Many types of human cells need to replicate or make copies of themselves. When a virus first enters the body it infects human cells and hijacks the machinery the cell normally uses to replicate and instead creates more copies of the virus. These viruses can then infect even more cells, setting off a vicious cycle of infection. With HIV, this has an especially disastrous effect because the primary cells infected by the virus are those of the human immune system and as they are infected and destroyed the immune system begins to break down.
Both cellular and humoral immune responses can stop this cycle by preventing HIV from infecting more cells, but they act at different stages. CTLs target cells that are already infected with the virus, while antibodies act on the virus before it enters the cell. A virus and a cell are like two puzzle pieces that fit together, but when an antibody attaches to the virus it comes between the two, blocking them from connecting. The HIV puzzle piece is the virus's envelope protein, also known as gp120. The cellular piece of the puzzle is the CD4 receptor protein on the surface of the CD4+ T helper cells, the primary target of HIV. The receptor protein is what HIV attaches to and uses to gain entry into the cell.
Since antibodies could stop a virus like HIV in its tracks, or neutralize it, they will be a particularly important component of a future AIDS vaccine candidate that could prevent people who are exposed to HIV from becoming infected. Many existing vaccines—including those against measles, hepatitis A and B, and polio—work because they induce virus-specific antibodies that are capable of protecting against infection.
Not all antibodies are created equal
To learn more about the types of antibodies that are produced in response to HIV, researchers have closely analyzed the immune responses in HIV-infected individuals at various times during the course of their infection. They have found that many types of HIV-specific antibodies are produced by the humoral immune system, but very few of them are capable of actually binding to the virus and neutralizing it. Those select few antibodies that can successfully stop the virus from infecting cells are known as neutralizing antibodies. Antibodies that can effectively neutralize many different strains of HIV are called broadly neutralizing antibodies. These are very rare and so far only a handful have been identified.
HIV has several tricks it uses to avoid being neutralized by antibodies. One is that the virus can change itself, or mutate, very rapidly. This mutation can be a slight change in the virus's shape or structure. Most HIV-infected individuals produce HIV-specific antibodies soon after becoming infected. But even in the short amount of time it takes for the adaptive immune system to gear up and start producing HIV-specific antibodies, the virus can alter itself so dramatically that the antibody no longer recognizes the majority of the virus in the body and is therefore ineffective.
Another reason why there are so few broadly neutralizing antibodies against HIV is that the virus itself is coated in bulky sugar molecules that act as a shield, effectively blocking the antibodies from reaching their target. In fact the region of the HIV envelope protein—gp120—that antibodies would latch on to is the most heavily protected viral protein scientists have ever studied.
Vaccine strategy
There has been little success to date in inducing broadly neutralizing antibodies through vaccination. Recently however a team of researchers in the US has discovered a possible chink in HIV's protective armor. When studying the exact site where one of the already-identified broadly neutralizing antibodies binds to the virus, researchers found it was the precise place where the virus would connect to the CD4 receptor protein on cells, blocking the two from fitting together. Another promising finding is that this CD4-binding region on gp120 is highly conserved—meaning it doesn't mutate as much—since this region of the virus is needed to attach to human cells. This means that this site should be similar in most strains of HIV. This exciting news provides a new window of opportunity for AIDS vaccine researchers to design vaccine candidates that can induce antibodies to target this vulnerable point on the virus.
www.iavireport.org/vax/english/VAX_Fe...
*********************************

IAVI database of AIDS vaccines in human trials
Last updated: February 23, 2007
www.iavireport.org/specials/OngoingTr...

[verwijderd] 1 maart 2007 08:02

0

quote:
aossa schreef:
Drug:MK0518

Raltegravir, was formerly known as MK-0158.

Researchers hail 2 new AIDS drugs

Therapies promising for patients resistant to existing HIV meds
Sabin Russell, Chronicle Medical Writer
Wednesday, February 28, 2007
(02-28) 04:00 PST Los Angeles -- Two new AIDS drugs, which work differently than any available HIV medications, have been found to be highly successful at suppressing the virus in patients who have exhausted available treatment options, researchers said Tuesday.
In an evening session of the 14th Conference on Retroviruses and Opportunistic Infections, scientists from Merck and Pfizer presented results from major studies conducted as a requirement to submitting the new medications to the Food and Drug Administration for approval.
In two separate studies run by New Jersey pharmaceutical giant Merck & Co. Inc., its experimental antiviral drug Raltegravir was shown to be safe and able to knock down HIV to undetectable levels in 60 percent of those who took it; while levels were brought to what is deemed a manageable level in 80 percent of patients.
A different set of twin studies was carried out by Pfizer Inc. of New York on a different experimental drug called Maraviroc, which showed at least 45 percent of those who took it suppressed HIV to undetectable levels, and 60 percent brought it to manageable levels.
"This is really a remarkable development in the field,'' said University of Pittsburgh School of Medicine researcher Dr. John Mellors.
He compared the findings of 60 to 80 percent effectiveness to the stunning news a decade ago of the first reports that combinations of existing AIDS drugs were suppressing HIV by similar amounts in patients who until then had no effective treatments.
Those patients who contracted HIV in the early 1980s and burned through nearly two-dozen different antiviral drugs to survive to this day are among those likely to benefit most from the two new drugs if they eventually win FDA approval.
Pfizer has already submitted an application for FDA approval for its drug, and Merck is expected to file for approval this spring.
According to the Merck studies, 98 percent of one group of 44 men controlled their virus when they took the Merck drug in combination with a newly approved drug called Prezista and a costly injectable antiviral medication known as Fuzeon. That duo of new drugs today is prescribed mostly to patients who have become resistant to almost all known AIDS drugs.
Merck's new drug is the first of a new class of potential HIV drugs called "integrase inhibitors.'' It targets an enzyme made by the virus when it invades a blood cell and tries to plant a copy of itself in the DNA of its prey. Nearly all other successful AIDS drugs target one of two other enzymes, reverse transcriptase or protease, which also help HIV make copies of itself inside a cell.
Pfizer's new drug also takes on a new molecular target -- a kind of latch on the surface of white blood cells that HIV commandeers before it slips inside. The latch, called CCR5, was discovered in 1996, but subsequent efforts to develop a drug that jams it have been, until now, disappointing.
www.sfgate.com/cgi-bin/article.cgi?fi...

Zie ook www.retroconference.org/2007/data/fil...

[verwijderd] 1 maart 2007 08:39

0

Great news Flosz!

PSDat is nog eens wat anders dan het condoomverbod van die Sinterklaas in Rome, c.q. de Paus..

[verwijderd] 1 maart 2007 08:53

2

quote:
ruli schreef:
Great news Flosz!

PSDat is nog eens wat anders dan het condoomverbod van die Sinterklaas in Rome, c.q. de Paus..

M.b.t. Merck-MK0518: geen Crucell inside.
MK-0518, ontwikkeld door Merck, Sharp & Dohme (MSD), is mogelijk de eerste van een nieuwe klasse experimentele antiretrovirale geneesmiddelen (ART), de zogenaamde integraseremmers.
www.nieuwsbank.nl/inp/2005/11/21/F053...

MRKAd5 HIV-1 gag/pol/nef/MRKAd5 trivalent, Crucell-inside.
Zie o.a.
www.iex.nl/forum/topic.asp?forum=228&...
chi.ucsf.edu/vaccines/vaccines?page=v...
www.genengnews.com/articles/chitem.as...
hugin.info/132631/R/983544/146425.pdf
www.hvtn.org/media/press_releases.sht...
www.hvtn.org/faq/503/HVTN503FAQ_eng.pdf
www.hvtn.org/science/trials.html
www.hvtn.org/ppt/oct06/RobertsonStep.... :Update on the STEP Study Merck V520 Protocol 023/HVTN 502 October 2006.
MRKAd5 HIV-1 gag/pol/nef trivalent vaccine, Grown in PER.C6 cells (Crucell), Pagina 5.

[verwijderd] 1 maart 2007 15:07

0

AVI BioPharma Presents Novel HIV Drug Candidate ResultsLast update: 3/1/2007 9:00:24 AMCell-Culture Research Targets HIV-1 Vif and Tar Stem Loop PORTLAND, Ore., Mar 01, 2007 (BUSINESS WIRE) -- AVI BioPharma, Inc. (AVII), presented research results titled "Morpholino Antisense Oligomers that Target the Lentiviral Vif Gene and Tar Stem Loop are Novel Antiretroviral Drug Candidates" at the 14th Annual Conference on Retroviruses and Opportunistic Infections (CROI), held this week in Los Angeles. Richard K. Bestwick, Ph.D., director of antiretroviral research for AVI, presented the results in poster form. Dr. Bestwick reported on AVI's investigations into the feasibility of novel antiviral targets: the HIV-1 viral infectivity factor (Vif) and the HIV-1 transactivation response element (Tar) stem loop. These targets are considered integral to viral replication and protein expression, respectively. The viral genome target sites were selected in part due to their presence in all known viral isolates. The antiviral potential of these targets was evaluated with AVI compounds in test tube (in vitro translation) and cell-culture studies. The studies suggested that the targets are promising candidates for further investigation in more sophisticated cell-culture systems and in animal models. "New approaches to antiviral therapy for HIV-1 are needed," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI BioPharma. "These studies add to our growing understanding of antisense approaches to treat viral infections, specifically HIV-1, which represents one of the most challenging areas for antiviral therapy." About AVI BioPharma AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at .

Dirk

[verwijderd] 12 april 2007 13:52

1

.....MRKAd5 HIV-1 gag/pol/nef trivalent vaccine, Grown in PER.C6 cells

[verwijderd] 12 april 2007 22:34

0

Wat bedoel je?

flosz 7 april 2008 13:31

0

Even plakken....met een dikke zoen @ gogogoo!

www.iex.nl/forum/topic.asp?forum=228&...

Meer, veel meer via:
crucell.yourbb.nl/viewtopic.php?f=7&t...

flosz 12 mei 2008 16:04

3

AIDS vaccine research:
FAQS
09 May 08
www.iavi.org/viewfile.cfm?fid=48432

AIDS vaccines in perspective
09 May 08
www.iavi.org/viewfile.cfm?fid=48434

Myths & Misconceptions
09 May 08
www.iavi.org/viewfile.cfm?fid=48433

We Are Making Progress on AIDS
In an opinion piece published in the Wall Street Journal, IAVI President and CEO Seth Berkley challenges the pessimism surrounding recent AIDS vaccine media coverage and states that there are sound scientific reasons to believe we can create a vaccine against AIDS.
www.iavi.org/viewfile.cfm?fid=48353

Originally aired as part of BBC World’s Kill or Cure? series, this four-minute documentary features AIDS specialists, researchers, and community workers discussing the impact of HIV/AIDS on their communities and their efforts to find a solution to the epidemic
www.iavi.org/homepage/videopopup.cfm?n

New Market Tax Credit Helps Finance IAVI AIDS Vaccine Development Lab Construction
The National Community Fund I, LLC and Greystone CDE, LLC have chosen IAVI’s new AIDS Vaccine Development Laboratory to be the recipient of a New Markets Tax Credit, a financing program designed to spur investment in businesses and create jobs in low-income communities
www.iavi.org/viewfile.cfm?fid=48335

On May 18, AIDS vaccine advocates worldwide mark World AIDS Vaccine Day by acknowledging all who work tirelessly to find a safe and effective AIDS vaccine, the world's best hope for ending the AIDS pandemic
www.iavi.org/viewpage.cfm?aid=1925

The search for a vaccine
www.broadcastyoutube.com/watch?v=k73s...

flosz 19 mei 2008 20:43

0

The Search Must Continue.

3 The Story that Must be Told: A letter from the Executive Director
7 AVAC’s Top 10 Recommendations for 2008 and Beyond
9 AVAC Report 2008 At a Glance
11 Status Report: An Update on Last Year’s Recommendations
13 Chapter 1 The Whole Wide World: Global priorities around HIV prevention research
13 Our Top Priorities
21 Chapter 2 What’s (Y)our Position?: Where we stand in the post-STEP era
29 Community Input on PAVE 100: What does “GPP” say?
33 Chapter 3 What We Know for Sure: Lessons to be learned from the STEP study
40 Towards an African-American AIDS Research Agenda: Required Reading
41 Chapter 4 Moving Forward, Looking Back: Studying the IAVI model
46 Mobilizing Resources, Managing Expectations
52 Science Snapshot: Quick takes on next steps in the search for an AIDS vaccine
55 Time for the Enterprise to Expand its Impact
56 The Search Continues

FIGURES & TABLES
14 Figure 1 HIV Prevention Research: A Comprehensive Timeline of Anticipated Results from Efficacy Trials
17 Table 1 Ongoing and Planned PrEP Trials as of April 2008
18 Figure 2 Ongoing Trials of New Prevention Options Worldwide (April 2008)
22 Figure 3 The Era of Flat Funding: NIH and NIAID AIDS Research Funding FY 1989-2009
25 Figure 4 Losing Power: The Impact of Inflation on the Flat NIH Budget
26 Table 2 Ongoing Trials of Preventive HIV/AIDS Vaccines Worldwide (April 2008)
32 Figure 5 Why an AIDS Vaccine Is Possible
33 Figure 6 Starting the “Post-STEP” Era: A Timeline
34 Figure 7 All in This Together: Layers of the AIDS Vaccine Community
35 Figure 8 Projected HIV Prevalence By Age: US and African-American MSM
36 Figure 9 HIV Prevalence by Age Among US and African-American MSM: Current Estimates
37 Figure 10 Data on Rates of Reported Risk Behavior Among Male Volunteers in the STEP Trial
38 Table 3 Proportion of STI Prevention Expenditures Targeted at MSM in Asia
42 Figure 11 Annual Public and Philanthropic Investments in Preventive HIV Vaccine R&D
from 2000 to 2006
43 Figure 12 Financing the Search
49 Figure 13 Global Distribution of Vaccine Trial Sites
www.avac.org/pdf/reports/2008_Report/...

flosz 2 juni 2008 11:44

1

AIDS Vaccine Research Subcommittee
Bethesda North Marriott Hotel & Conference Center
5701 Marinelli Road, Bethesda, Maryland 20852
Room: Salon A-C
Date: Friday, May 30, 2008
10:45
PAVE 100 team proposal
Scott Hammer, Peter Gilbert
Webcast:
www.macrovolt.com/live/dgi_053008/

Bloombergart.GenVec/Vical:Zie post Gert50(AB&dankjewel):
AIDS Vaccine Linked to Failed Merck Product Nears Human Testing
www.bloomberg.com/apps/news?pid=20601...

www.iex.nl/forum/topic.asp?forum=228&...
****************************
Table of HVTN Vaccine Trials

Updated May 2008

10X Closed to accrual.

chi.ucsf.edu/vaccines/images/p01-vc/s...

[verwijderd] 2 juni 2008 12:43

0

Dit draadje is inderdaad beter ivm HIV etc. berichten, had het niet in de gaten. Dank je wel Flosz.

flosz 10 juni 2008 20:26

3

Tuesday, June 10, 2008
• 9:45 a.m. EST: Dr. Fauci will address the 2008 United Nations General Assembly High-Level Meeting on AIDS.
• 12:30 p.m. EST: Dr. Fauci will participate in a press conference with U.N. President of the General Assembly Srgjan Kerim.
U.N. Headquarters, 1st Ave. and 46th St., New York, New York
NIAID Director Anthony S. Fauci, M.D., is available to comment.
**************************
Decades may be necessary to develop HIV vaccine, US says

Jun 10, 2008, 15:59 GMT
New York - The United States told the United Nations Tuesday that a vaccine against the AIDS virus remains elusive 27 years after the epidemic began and could take decades more to develop.
A second day of UN debate on efforts against HIV/AIDS shifted into high-level government discussions on Tuesday.
Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, told the UN General Assembly that clinical tests of an HIV vaccine were disappointing last year.
He said an effective vaccine could take decades to develop and that the AIDS virus has shown its 'uncanny ability to elude the body's natural attempt to contain it.'
'HIV has proven to be very different from those viruses for which we have developed effective immunization,' Fauci said. 'Historically it has taken decades to find effective vaccines to combat most infectious diseases.'
The first known AIDS victims were five gay men in San Francisco, whose cases were reported by the US Centers for Disease Control and Prevention this week in 1983. The UN said more than 25 million people have died of AIDS since then and more than 42 million people are now living with HIV worldwide.
The UN reported that some progress has been made toward its goal of halting and reversing the spread of AIDS by 2015. But it said also that new cases of infections - 2.5 million last year - outpaced all efforts to provide anti-retroviral treatment in poor countries. A total of 1 million people received the treatment last year.
Germany's Minister of Health Ulla Schmidt warned in a prepared speech that the UN goal of providing access to treatment to infected people may not be reached by 2010, another UN benchmark goal on treatment. She said the world's eight most industrialized nations, or G-8, decided last year to provide 60 billion dollars to fight HIV/AIDS, including 4 billion euros (6.2 billion dollars) from Germany by 2015.
She said Germany plans to contribute 600 million euros by 2010.
'In this process, political leadership is vital and has to be assumed by heads of state and government unambiguously, in order to build up infrastructure and to overcome discrimination, including HIV-specific travel restrictions,' she said.
The world spent 10 billion dollars last year to fight the epidemic.
UN Secretary General Ban Ki-moon opened the high-level discussion, calling for scaling up the levels of commitment and financing by governments in order for the UN to halt new cases of infections by 2015.
'How we fare in fighting AIDS will impact all our efforts to cut poverty and improve nutrition, reduce child mortality and improve maternal health, curb the spread of malaria and tuberculosis,' he said.
The UN conference was called to review progress made and map new strategies to reach the 2015 deadline.
www.monstersandcritics.com/news/healt...
article_1410367.php/Decades_may_be_necessary_to_develop_HIV_vaccine_US_says

aossa 11 juni 2008 18:48

0

Peter Piot verlaat UNAIDS

De directeur van UNAIDS (Joint United Nations Programme on HIV/AIDS), de Belg Peter Piot, heeft beslist om op het einde van het jaar zijn functie stop te zetten. Dat meldde de secretaris-generaal van de VN, Ban Ki-moon, zo schreven dinsdag Engelstalige media.

(belga) - Ban kondigde het vertrek van Piot aan op de achtste VN-conferentie over hiv/aids in New York.

Dokter Piot, die in 1976 mede-ontdekker was van het Ebolavirus in Zaïre (nu Democratische Republiek Congo), leidt UNAIDS al sinds haar oprichting in 1995. Hij was voordien professor Microbiologie aan de Universiteit van Antwerpen en aan het Instituut voor Tropische Geneeskunde.

Piot had in april al bekendgemaakt dat hij van plan was om zijn functie op het einde van het jaar te beëindigen. Hij zei dinsdag dat hij wellicht opnieuw de academische weg inslaat. Zijn opvolger moet nog aangeduid worden door de VN-instanties en benoemd worden door de secretaris-generaal van de VN.

flosz 7 juli 2008 16:56

0

ATLANTA, July 7 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based, publicly traded biopharmaceutical company specializing in the prevention and treatment of infectious diseases, today provided an operational update on the company's progress towards entering Phase 2 preventative human clinical trial testing and plans to proceed into therapeutic human trials with its AIDS vaccine. Five successful human trials evaluating GeoVax AIDS vaccines have previously been reported.
Planned Phase 2 Human Clinical Trial for Prevention of AIDS
The Company's Phase 2 trial, conducted by the U.S. National Institutes of Health (NIH) supported HIV Vaccine Trials Network (HVTN), will involve 225 healthy volunteers from the United States and South America, and will further evaluate the safety and immunogenicity of the GeoVax preventative vaccine (vaccine administered prior to infection with the HIV virus). In Phase 1 trials, both 1/10th dose and full dose of the GeoVax vaccine elicited anti-HIV T-cells, whereas the full dose was required to elicit good frequencies of antibody to the HIV Envelope glycoprotein. The larger Phase 2 human trial will broaden the base of safety and immunogenicity data for the full dose of the GeoVax AIDS vaccine with a view to protecting recipients from developing AIDS should they be exposed to the virus. The planned Phase 2 human clinical trial is currently scheduled to start early this fall, subject to FDA approval.
Preclinical Data for Use of Vaccine Technology as an AIDS Therapeutic
Human Clinical Trials in Planning Stages
GeoVax also announced summary data from a pilot study on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the SIV prototype for the GeoVax AIDS vaccine. In this small pilot study, conducted by Dr. Amara at Emory University, two non-human primates were infected with SIV. At 12 weeks post SIV infection, conventional anti-viral drug therapy was given to the primates to reduce the viral RNA infection levels to very low levels creating a non progressor status for the primate. Then the SIV prototype vaccine for the GeoVax AIDS vaccine was administered. Six weeks following the final vaccination, anti-viral drug treatment was stopped and the animals were monitored to determine whether the vaccine could control the SIV infection during the absence of the drugs.
The outstanding results from the study revealed the vaccine controlling the infection in the absence of drugs. In one primate, the reduction in viral levels over pre-drug treatment and vaccination levels was 1000 times. In the other, the reductions in viral levels were 100 times. The excellent control of the virus infection in the absence of drug treatment was associated with the vaccine raising the types of CD4 and CD8 T cells that are found in the rare individuals who spontaneously control their HIV infections.
Based on these excellent results, planning for a therapeutic trial in infected and drug treated humans has been initiated. The intent of therapeutic vaccination is for the vaccine to "control" HIV virus levels in infected individuals to very low levels thus blocking the development of AIDS. Successful therapeutic AIDS vaccination programs with GeoVax vaccines would lead to reduction in the use of costly anti-HIV medications and their often harmful side effects.
Dr. Harriet Robinson, GeoVax Co-founder and Senior V.P. of Research and Development, commented, "I had not anticipated the extent of vaccine control that was achieved in the already infected non-human primates. These are highly promising results that need to be extended into infected humans to see if the vaccine can be used to reduce the need for taking drugs. The results also warrant more extended studies in already infected non-human primates to explore parameters that both limit and enhance the ability for a vaccine to displace the need for drugs."
Dr. Robert McNally, CEO and President of GeoVax Labs, Inc., emphasized, "It is noteworthy to mention that the GeoVax AIDS vaccines being tested in the preclinical therapeutic trial is the same basic vaccine administered in the Company's human trials testing for a preventative use of the vaccine, vaccinating people before infection to prevent the development of AIDS should they become infected. Thus, a "one for two" vaccine could be a breakthrough solution for the company and the world, saving millions of dollars in redundant development costs and years of testing time by utilizing safety data already achieved in Phase 1 preventative human trials. More important, time to market could be significantly reduced, saving lives much sooner than otherwise."
www.earthtimes.org/articles/show/geov...,457534.shtml
********************************
Nearing a decision on PAVE
www.iavireport.org/Vax/English/ECurre...
www.iavireport.org/Issues/ECurrent.pdf

[verwijderd] 25 juli 2008 16:53

0

New Ideas, More Money Needed for HIV Vaccine Search
July 25, 2008

US researchers say new ideas, new people and more money needed to search for HIV vaccine

By KEVIN FREKING

Associated Press Writer

423 words

24 July 2008

14:33

Associated Press Newswires

English

(c) 2008. The Associated Press. All Rights Reserved.

WASHINGTON (AP) - Scientists will have to take "enormous intellectual leaps" to develop an AIDS vaccine in the coming years, say U.S. researchers clearly frustrated by the failure of a once-promising shot.

The researchers, including a top National Institutes of Health official, want new people with new ideas to step up and join the search. They say the focus of their research should be on discovering a vaccine rather than on clinical trials for evaluating medicines that may or may not work.

"Design of a vaccine that blocks HIV infection will require enormous intellectual leaps beyond present day knowledge," concluded a broad team of researchers writing in Friday's edition of the journal Science.

More than 6,500 new HIV infections occur daily worldwide. A recent high-profile trial of a potential vaccine not only failed to prevent infection, but those who got the inoculation appeared at increased risk of infection compared with those who were given a placebo.

After the disappointing results, the National Institute of Allergy and Infectious Diseases held a summit in March on how to reinvigorate vaccine research.

The institute will still support studies in people -- but it is raising the bar that candidate vaccines need to pass to get federal support. NIH is looking for fresh ideas on how to approach HIV vaccine discovery, and emphasizing basic laboratory research to fill in key gaps in knowledge. Among the priorities will be increased research in chimpanzees, the Science article says.

The recent failed vaccine study showed "we were maybe on the wrong track a bit," Dr. Anthony Fauci, the institute's director, told a Science podcast. "We will be turning the knob, as I like to say, more preferentially toward answering some of the fundamental questions that have gone unanswered," he said.

When contractors don't meet milestones, or when initiatives don't attract the highest quality of applications, money will be redirected to more promising research activities, Fauci's team wrote. Unfortunately, the need for more resources aimed at discovering a vaccine comes at a time when the National Institutes of Health's budget remains flat, the officials said.

"Should growth in the NIH budget be reinstated in future years, one of the highest priorities will be to target those additional resources to HIV vaccine programs, particularly vaccine discovery research," the health officials wrote.

AEX 937,32 -1,26 -0,13% 10:42


Germany40^	22.325,30	+0,05%
BEL 20	4.373,79	+0,10%
Europe50^	5.467,10	+0,11%
US30^	44.225,40	+0,09%
Nasd100^	22.100,70	+0,14%
US500^	6.119,90	+0,01%
Japan225^	38.824,70	+0,62%
Gold spot	2.927,12	-0,41%
EUR/USD	1,0475	-0,22%
WTI	72,03	-0,54%

HEIJMANS KON	+10,04%
Brunel	+4,33%
ALLFUNDS GROUP	+2,35%
BAM	+1,85%
JDE PEET'S	+1,83%

PostNL	-4,39%
BESI	-4,02%
EBUSCO HOLDING	-2,62%
WDP	-2,45%
NX FILTRATION	-1,83%

Crucell « Terug naar discussie overzicht

Draadje HIV/AIDS

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers